Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Rectal Neoplasms 3Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 5liposomal doxorubicin 4Topotecan 3Doxorubicin 2Carboplatin 2Bevacizumab 2saracatinib 1pegfilgrastim 1olaparib 1cediranib 1atezolizumab 1Taxes 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Ifosfamide 1Gemcitabine 1Disulfides 1Diathermy 1Chemotherapy, Adjuvant 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Fallopian Tube Neoplasms × Neoadjuvant Therapy × Clear all
NCT00075712 2013-08-12

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
150 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡